Close

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OM

Go back to Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OM
(NASDAQ: SGHT) Delayed: 5.62 -0.02 (0.35%)
Previous Close $5.64    52 Week High
Open $5.57    52 Week Low
Day High $5.83    P/E N/A 
Day Low $5.43    EPS
Volume 84,702